EARLY: Prospective, Randomised, National, Multi-Centre, Open-Label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-Day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study.

Trial Profile

EARLY: Prospective, Randomised, National, Multi-Centre, Open-Label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-Day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2014

At a glance

  • Drugs Aspirin/dipyridamole (Primary) ; Aspirin
  • Indications Embolism and thrombosis; Stroke; Transient ischaemic attacks
  • Focus Therapeutic Use
  • Acronyms EARLY
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Mar 2010 Actual number of patients changed from 548 to 551 as reported by ClinicalTrials.gov.
    • 01 Feb 2010 Results were published in the Lancet Neurology 9: 159-66, No.2.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top